Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Recruiting · NCT05746208 · Registry updated 2026-03-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-03-17 | NCT05746208 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| University of California, San Francisco | 637 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California, San Francisco | San Francisco | United States | 294 |